Mark A Hull

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1155718/publications.pdf

Version: 2024-02-01

85 papers	3,667 citations	136885 32 h-index	133188 59 g-index
89 all docs	89 docs citations	89 times ranked	5405 citing authors

#	Article	IF	Citations
1	A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut, 2018, 67, 1974-1983.	6.1	332
2	Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview. Cancer Prevention Research, 2012, 5, 164-178.	0.7	242
3	Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut, 2010, 59, 918-925.	6.1	201
4	Localization of Cyclooxygenase-2 in Human Sporadic Colorectal Adenomas. American Journal of Pathology, 2000, 156, 545-553.	1.9	200
5	Macrophage Migration Inhibitory Factor Promotes Intestinal Tumorigenesis. Gastroenterology, 2005, 129, 1485-1503.	0.6	140
6	Increased Risk of Colorectal Cancer After Obesity Surgery. Annals of Surgery, 2013, 258, 983-988.	2.1	132
7	Excess body weight and obesityâ€"the link with gastrointestinal and hepatobiliary cancer. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 224-238.	8.2	102
8	Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2â€ˆÂ—â€ˆ2 factorial trial. Lancet, The, 2018, 392, 2583-2594.	6.3	102
9	Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Gut, 2014, 63, 1760-1768.	6.1	93
10	Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer?. Molecular Cancer Therapeutics, 2004, 3, 1031-9.	1.9	90
11	Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the ApcMin/+ mouse. Gastroenterology, 2001, 121, 889-899.	0.6	85
12	FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCÎ³/COX-2-Mediated Mechanisms. PLoS ONE, 2012, 7, e38972.	1.1	82
13	Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis, 2002, 23, 107-114.	1.3	81
14	The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology, 2003, 125, 716-729.	0.6	78
15	Increasing Prescription of Opiates and Mortality in Patients WithÂInflammatory Bowel Diseases in England. Clinical Gastroenterology and Hepatology, 2018, 16, 534-541.e6.	2.4	74
16	A risk-stratified approach to colorectal cancer prevention and diagnosis. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 773-780.	8.2	74
17	Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitisâ€associated colorectal cancer acting on Notch signaling and gut microbiota. International Journal of Cancer, 2014, 135, 2004-2013.	2.3	73
18	Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut, 2018, 67, 179-193.	6.1	73

#	Article	IF	Citations
19	Effect of Eicosapentaenoic Acid on E-type Prostaglandin Synthesis and EP4 Receptor Signaling Human Colorectal Cancer Cells. Neoplasia, 2010, 12, 618-IN2.	2.3	72
20	Activity of the non-steroidal anti-inflammatory drug indomethacin against colorectal cancer. Cancer Treatment Reviews, 2003, 29, 309-320.	3.4	70
21	Cyclooxygenase-2: How good is it as a target for cancer chemoprevention?. European Journal of Cancer, 2005, 41, 1854-1863.	1.3	67
22	Folic Acid Supplementation May Reduce Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2017, 51, 247-253.	1.1	67
23	Omega-3 polyunsaturated fatty acids as adjuvant therapy of colorectal cancer. Cancer and Metastasis Reviews, 2018, 37, 545-555.	2.7	64
24	Increased Colorectal Epithelial Cell Proliferation and Crypt Fission Associated with Obesity and Roux-en-Y Gastric Bypass. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1401-1410.	1.1	59
25	Lymphodepletion in the ApcMin/+ mouse model of intestinal tumorigenesis. Blood, 2004, 103, 1050-1058.	0.6	54
26	Obesity surgery and risk of colorectal and other obesity-related cancers: An English population-based cohort study. Cancer Epidemiology, 2018, 53, 99-104.	0.8	53
27	Omega-3 polyunsaturated fatty acids. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 547-554.	1.0	45
28	The omegaâ€3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MCâ€26 colorectal cancer cell liver metastasis via inhibition of PGE₂â€dependent cell motility. British Journal of Pharmacology, 2012, 166, 1724-1737.	2.7	45
29	Rectal epithelial cell mitosis and expression of macrophage migration inhibitory factor are increased 3 years after Roux-en-Y gastric bypass (RYGB) for morbid obesity: implications for long-term neoplastic risk following RYGB. Gut, 2011, 60, 893-901.	6.1	42
30	Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells. Oncogene, 2002, 21, 7175-7186.	2.6	39
31	Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas. Journal of Pathology, 2002, 198, 435-441.	2.1	36
32	A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 237.	0.7	36
33	Colon and rectal cancer risk after bariatric surgery in a multicountry Nordic cohort study. International Journal of Cancer, 2020, 147, 728-735.	2.3	34
34	Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?. World Journal of Gastroenterology, 2016, 22, 3679.	1.4	32
35	Decreasing Risk of First and Subsequent Surgeries in Patients With Crohn's Disease in England From 1994 throughÂ2013. Clinical Gastroenterology and Hepatology, 2019, 17, 2042-2049.e4.	2.4	31
36	Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2016, 10, 1144-1150.	0.6	30

#	Article	IF	Citations
37	Cyclooxygenase-2 expression in colorectal cancer liver metastases. Clinical and Experimental Metastasis, 2000, 18, 21-27.	1.7	29
38	Colorectal Cancer Prognosis Following Obesity Surgery in a Population-Based Cohort Study. Obesity Surgery, 2017, 27, 1233-1239.	1.1	29
39	Regulation of stromal cell cyclooxygenase-2 in the Apc Min/+ mouse model of intestinal tumorigenesis. Carcinogenesis, 2006, 27, 382-391.	1.3	28
40	446 High Definition White Light Endoscopy (Hdwle) Versus High Definition With Chromoendoscopy (Hdce) in the Detection of Dysplasia in Long Standing Ulcerative Colitis: a Randomized Controlled Trial. Gastrointestinal Endoscopy, 2015, 81, AB148.	0.5	27
41	Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases. Prostaglandins Leukotrienes and Essential Fatty Acids, 2016, 115, 60-66.	1.0	26
42	Marine omegaâ€3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). International Journal of Cancer, 2019, 145, 380-389.	2.3	22
43	Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human caseâ€“control epidemiological observations. Carcinogenesis, 2013, 34, 2341-2349.	1.3	20
44	Mucosal biomarkers of colorectal cancer risk do not increase at 6 months following sleeve gastrectomy, unlike gastric bypass. Obesity, 2014, 22, 202-210.	1.5	20
45	Urgent improvements needed to diagnose and manage Lynch syndrome. BMJ: British Medical Journal, 2017, 356, j1388.	2.4	20
46	Nutritional prevention of colorectal cancer. Proceedings of the Nutrition Society, 2021, 80, 59-64.	0.4	20
47	A liquid chromatographyâ€“tandem mass spectrometry method to measure fatty acids in biological samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1055-1056, 125-134.	1.2	18
48	Bialellic Mutations in Tetratricopeptide Repeat Domain 7A (TTC7A) Cause Common Variable Immunodeficiency-Like Phenotype with Enteropathy. Journal of Clinical Immunology, 2017, 37, 617-622.	2.0	18
49	Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the Apc Min/+ mouse model of intestinal tumorigenesis. Scientific Reports, 2017, 7, 6074.	1.6	17
50	Aspirin Users Attending for NHS Bowel Cancer Screening Have Less Colorectal Neoplasia: Chemoprevention or False-Positive Faecal Occult Blood Testing?. Digestion, 2012, 85, 278-281.	1.2	15
51	Nutritional Agents with Anti-Inflammatory Properties in Chemoprevention of Colorectal Neoplasia. Recent Results in Cancer Research, 2013, 191, 143-156.	1.8	15
52	Obesity and colorectal cancer. Gut, 2014, 63, 205.1-205.	6.1	15
53	Expression of prostaglandin D2 receptors DP1 and DP2 by human colorectal cancer cells. Cancer Letters, 2004, 210, 81-84.	3.2	14
54	Cancer risk after bariatric surgery â€" is colorectal cancer a special case?. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 653-654.	8.2	14

#	Article	IF	Citations
55	Colonoscopy for colonic wall thickening at computed tomography: a worthwhile pursuit?. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 2586-2591.	1.3	13
56	The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid. BioMed Research International, 2015, 2015, 1-8.	0.9	13
57	Omega-3 polyunsaturated fatty acids: moving towards precision use for prevention and treatment of colorectal cancer. Gut, 2022, 71, 822-837.	6.1	13
58	Atherosclerosis and Colorectal Carcinogenesis: Shared Risk Factors or Common Pathogenesis?. Digestion, 2010, 81, 16-17.	1.2	12
59	Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis. Oncotarget, 2016, 7, 28139-28150.	0.8	12
60	Analysis of Cyclooxygenase Expression in Human Colorectal Adenomas. Diseases of the Colon and Rectum, 2002, 45, 1316-1324.	0.7	11
61	Beyond cardiovascular medicine: potential future uses of icosapent ethyl. European Heart Journal Supplements, 2020, 22, J54-J64.	0.0	9
62	High-Frequency Ultrasound for InÂVivo Measurement of Colon Wall Thickness in Mice. Ultrasound in Medicine and Biology, 2012, 38, 432-442.	0.7	8
63	Regional differences in prostaglandin E2 metabolism in human colorectal cancer liver metastases. BMC Cancer, 2013, 13, 92.	1.1	7
64	A novel bioactive derivative of eicosapentaenoic acid (EPA) suppresses intestinal tumor development in Apcî”14/+ mice. Carcinogenesis, 2018, 39, 429-438.	1.3	7
65	Uncovering undiagnosed liver disease: prevalence and opportunity for intervention in a population attending colonoscopy. BMJ Open Gastroenterology, 2021, 8, e000638.	1.1	7
66	Eicosapentaenoic acid and/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-154.	0.9	7
67	Attitudes to out-of-programme experiences, research and academic training of gastroenterology trainees between 2007 and 2016. Frontline Gastroenterology, 2019, 10, 57-66.	0.9	6
68	Systematic review and metaâ€analysis: Associations between metabolic syndrome and colorectal neoplasia outcomes. Colorectal Disease, 2022, 24, 681-694.	0.7	5
69	Immunohistochemical measurement of endothelial cell apoptosis and proliferation in formalin-fixed, paraffin-embedded human cancer tissue. Angiogenesis, 2006, 9, 193-200.	3.7	4
70	Chemoprevention in gastroenterology. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 443.	1.0	4
71	Are there biological differences between screen-detected and interval colorectal cancers in the English Bowel Cancer Screening Programme?. British Journal of Cancer, 2016, 115, 261-265.	2.9	4
72	Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Chemotherapy and Pharmacology, 2021, 87, 173-184.	1.1	4

#	Article	IF	Citations
73	Luminal Bioavailability of Orally Administered Ï‰-3 PUFAs in the Distal Small Intestine, and Associated Changes to the Ileal Microbiome, in Humans with a Temporary Ileostomy. Journal of Nutrition, 2021, 151, 2142-2152.	1.3	4
74	Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERÎ±-positive breast cancer. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 355-371.	0.5	4
75	Using faecal immunochemical test (FIT) undertaken in a national screening programme for large-scale gut microbiota analysis. Gut, 2021, 70, gutjnl-2020-321594.	6.1	3
76	Molecular pathways leading to cancer as a basis for preventive strategies. Current Colorectal Cancer Reports, 2008, 4, 43-47.	1.0	2
77	Getting involved in clinical trials research in the UK: how can Clinical Research Networks help?. Frontline Gastroenterology, 2012, 3, 66-71.	0.9	2
78	Reply to Letter. Annals of Surgery, 2015, 262, e15-e16.	2.1	2
79	REducing Colonoscopies in patients without significant bowEl DiseasE: the RECEDE Study - protocol for a prospective diagnostic accuracy study. BMJ Open, 2022, 12, e058559.	0.8	2
80	The <scp>COLOâ€€COHORT</scp> (Colorectal Cancer Cohort) study: Protocol for a multiâ€€centre, observational research study and development of a consentâ€€forâ€€contact research platform. Colorectal Disease, 2022, 24, 1216-1226.	0.7	2
81	Role of miR-26b in carcinoma-associated fibroblasts and effect on migration and invasion of breast cancer epithelial cells. Lancet, The, 2014, 383, S103.	6.3	1
82	Successful delivery of clinical gastroenterology studies in the UK. Gut, 2015, 64, 854.1-856.	6.1	1
83	Reduction in the resident intestinal myelomonocytic cell population occurs during ApcMin/+ mouse intestinal tumorigenesis. Oncology Letters, 2021, 21, 263.	0.8	1
84	In vitro Models of Cox-2-Positive Macrophage-Epithelial Cell Interactions during Intestinal Tumorigenesis. Clinical Science, 2002, 103, 38P-38P.	0.0	0
85	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 1680-1681.	2.4	0